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toms. Among patients managed by office-based physicians (n753), oral antibiot-
ics and aminosalicylates (72% and 68% of patients, respectively) were the common
treatments. Among those managed by hospital-based physicians (n756), amin-
osalicylates were infrequently prescribed (11% of patients) and intravenous anti-
biotics were preferred over oral (67% and 36%, respectively). Fifty-seven percent of
patients were hospitalized, with the majority being for acute disease management
or diagnostics. Among those hospitalized, mean [SD] length of stay was 12.6 [31.8]
days. CONCLUSIONS: Diverticulitis presents a significant disease burden to health
care systems and patients in Europe. Many patients with diverticulitis present with
or develop serious complications, leading to frequent hospitalization and long hos-
pital stays.
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Spontaneous reporting of adverse drug reactions (ADRs) by health care staff using
the respective ADR reporting forms plays the key role in the Pharmacovigilance
system of various countries. Under-reporting of ADRs is a serious public health
issue. Occurrence of ADR varies from people to people and country to country. In
any given country, the ADR reporting form holds the key to collect vital ADR related
information. But, the structure and content of this form vary widely from country
to country.OBJECTIVES:The present study involved the collection and comparison
of ADR reporting forms of 55 different countries. METHODS: We analyzed the
uniformity of the forms by identifying 25 critical reporting parameters that assure
drug safety and ensure the casualty relationship between the drug and the ADR.
The non-English forms were translated using Google Translate. RESULTS: It re-
vealed through our study that only 8 out of 55 countries (14.5%) had at least 75% of
the parameters covered in their form. The ADR reporting form of Ukraine was
found to have 20 parameters (80%) covered. Following that, the ADR reporting
forms of India, Republic of China, and Malaysia covered 19 parameters (76%). Many
countries lack vital information about the patient. CONCLUSIONS: This study has
helped to identify the lack of information. There should be internationally recog-
nized uniform guidelines and checklists for designing of spontaneous reporting
forms. Though there are differences between the countries in gathering informa-
tion about suspected ADRs, the drug safety data from each country ultimately goes
to one single database – Vigibase. The reporting system and the forms used in most
of the developing nations should be improved, which in turn improves the quality
use of medicines in the respective country.
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OBJECTIVES: 1) To determine whether the use of duloxetine during pregnancy is
associated with an increased risk for major malformations; 2) examine rates of
spontaneous abortions(SA), therapeutic abortions(TA), stillbirths, as well as mean
birth-weight and gestational age at delivery; and 3) examine rates of Poor Neonatal
Adaptation Syndrome (PNAS) following late pregnancy exposure. METHODS: Data
was collected from either women or their health care providers who had requested
information regarding the use of duloxetine during pregnancy. The study design
was prospective, with two comparison groups, 1) exposed to other antidepressants,
and 2) exposed to non-teratogens (NTC). RESULTS: We completed 624 pregnancy
outcomes which included 208 in each group. Rates of major malformations were
similar across groups (p0.992). Significant differences were noted only in rates of
spontaneous abortions (p0.011) and admissions to neonatal intensive care unit/
special care nursery (p0.010). There were more preterm births in the duloxetine
group, although the results were not statistically different. There were 3/53 (5.6%)
cases consistent with PNAS symptoms in the duloxetine group with no evidence of
a dose response.CONCLUSIONS:Duloxetine does not appear to increase the rate of
major malformations above baseline. The higher rate of SA corroborates similar
results from other studies of antidepressant use in pregnancy. The incidence of
symptoms of PNAS in our study is somewhat lower than in prior studies reporting
on this outcome. These data add to the information regarding SNRI use in preg-
nancy, which will enable a woman, together with her physician, to make an evi-
dence-based decision regarding the use of duloxetine.
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OBJECTIVES: The University of Michigan Women’s Registry database contains in-
formation on 2,771 women. In addition to menopause diagnoses, the database
contains demographic characteristic, body mass index (BMI), menopause symp-
tom, hormone therapy, surgery, and other comorbidity information. This study
aims to compare the demographic and clinical characteristics between women
diagnosed with menopause versus those who were not, and explore the relation-
ship between menopause symptoms and diagnosis. METHODS: Demographic and
clinical characteristics between women diagnosed with menopause and those who
were not were compared descriptively. Mean and standard deviation were calcu-
lated for continuous variables, and numbers and percentages were calculated for
binary or categorical variables. T-test and Chi-square test were used to calculate
the p-values. RESULTS: Among all women in the registry (mean BMI: 29), 16%
(N443) were menopausal. Of this subset, 53.5% (N237) were treated with hor-
mone therapy. Hormone therapies included estrogen and progesterone combined
(58.67%), estrogen only (35.11%), soy/herbal remedies (4%), and raloxifene (2.22%).
For women with at least one menopausal symptom (N349), the most common
were hot flashes (59.60%) and vaginal dryness (59.60%). Non-menopausal women
were more likely to have hot flashes (66.67% vs. 49.76%, p-value0.007), mood
swings (56.06% vs. 25.12%, p-value0.001) and memory loss (55.30% vs. 39.23%,
p-value0.001) than menopausal women, which indicates that the menopause
diagnosis may be underestimated. This is consistent with the common issue found
in claims data, that menopausal women are not always diagnosed by physicians.
CONCLUSIONS: Women not diagnosed with menopause frequently had more
menopausal symptoms than women with diagnosed menopause. This may indi-
cate the underestimation of diagnosis. Therefore, it would be beneficial to use
menopausal symptoms as proxies to the diagnosis and control for them in the
research model. Techniques such as probabilistic linkage, could bridge the gap
between information in claims and registry data.
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In 2010, NICE published a clinical guideline on reducing the risk of venous throm-
boembolism (VTE) in patients admitted to hospital. At the time, five pharmological
VTE prophylaxis were recommended following elective knee or hip replacement
surgery—dabigatran etexilate, fondaparinux sodium, low molecular weight hepa-
rin (LMWH), rivaroxaban, and unfractionated heparin (UFH) for patients with renal
failure—in 2011, apixaban was also recommended for the same indication in the
UK. Although apixaban, dabigatran, and rivaroxaban were all assessed at different
times by NICE, each technology appraisal used a distinct methodology to compare
relevant interventions, directly and indirectly.OBJECTIVES:To evaluate the impact
of study identification methods and network size on indirect and mixed treatment
comparisons of pharmacological interventions for the prevention of VTE in pa-
tients undergoing elective orthopaedic surgery.METHODS:Data identification and
synthesis methods used in the NICE TA157, TA170, and TA245 were reviewed and
compared to best practice searching strategies and network meta-analysis meth-
odology. Literature searches specifically designed to collect data for use in network
meta-analysis were conducted and compared to original search results. Various
network sizes were tested to synthesise available evidence using Winbugs.
PRELIMINARY. RESULTS: Specifically designed search strategies to inform the ev-
idence base for network meta-analysis led to increased numbers of studies identi-
fied and included for synthesis increasing the total number of indirect comparisons
between existing VTE interventions. The impact of additional comparisons on rel-
ative treatment estimates was limited and precision did not increase.
CONCLUSIONS: Using a specific search strategy designed to optimise the identifi-
cation of studies for network meta-analysis allowed us to extend the network of
relevant studies; however, extending the network increased uncertainty in the
results and led to inconsistencies in the direct and indirect comparisons.
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OBJECTIVES: Countless studies have demonstrated that many emergency-room
visits and hospital admissions are drug-related and that a significant proportion of
these drug-related visits (DRV) are preventable. It has not been previously studied
which DRVs could be prevented through enhanced monitoring of therapy. The
objective of the study was to determine the incidence of DRVs attributed to labo-
ratory or physiologic abnormalities. METHODS: Three authors independently per-
formed comprehensive searches in relevant health care databases using pre-de-
termined search terms. Articles discussing DRV associated with poisoning,
substance abuse, or studied among existing in-patient populations were excluded.
Study country, year, sample, design, duration, DRV identification method, propor-
tion of DRVs associated with laboratory or physiologic abnormalities and associ-
ated medications were extracted. The three authors independently assessed se-
lected relevant articles according to the Strengthening the reporting of
observational studies in epidemiology (STROBE) and Consolidted Standards of Re-
porting Trials (CONSORT) guides as applicable according to the studies’
methodology. RESULTS: The initial literature search yielded a total of 1,780 articles
of which 43 articles meeting inclusion criteria and reporting sufficient laboratory or
physiologic data were included in the overall analysis. Half (52%) employed pro-
spective methodologies, which included both chart review and patient interview;
however, the overwhelming majorityof identified studies assessed only adverse
drug reactions (ADR) as a drug-related cause for DRV. Among the 43 studies, re-
ported DRV ranged between 0.4% and 40.9%, of which an association with labora-
tory or physiologic abnormalities represented 0.8% - 69.7% of cases. Most labora-
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